Cell Metab:武大李红良课题组发现代谢风险成为缺血性心脏病的主要驱动因素 

2021-09-03 haibei MedSci原创

最近李红良课题组及其合作课题组利用2019年全球疾病负担研究(GBD)报告的数据,分析了1990年至2019年期间204个国家和地区的IHD死亡人数和年龄标准化死亡率(ASDRs)。

近几十年来,经济的快速发展和社会的进步大大增加了代谢性危险因素的发生率,其中包括高收缩压(SBP)、高低密度脂蛋白胆固醇(LDL-c)、高空腹血浆葡萄糖(FPG)和高体重指数(BMI)。这些风险因素在个人和人群层面对健康有着广泛而深远的影响。 在全球范围内,缺血性心脏病(IHD)与所有心血管疾病(CVDs)中最高的疾病负担有关,其中包括急性心肌梗死、慢性稳定型心绞痛、慢性IHD及其相关的心力衰竭。2019年,与IHD相关的死亡总数达到914万,占所有CVD相关死亡人数的49.2%。因此,随着时间的推移,代谢性危险因素对IHD死亡的影响值得调查。 武汉大学李红良课题组长期关注代谢性疾病及其对CVD的贡献,他们注意到,代谢性危险因素发生率的大幅增加阻碍了人们对各种CVD发病率和相关死亡率的控制,包括IHD在内。对于占世界人口80%以上的发展中国家来说,解决这一日益增长的预防和治疗需求变得尤为迫切,这些国家的疾病模式正在从以传染病为主转向以非传染性疾病(NCDs)为主。因此,对整体IHD负担、其流行病学特征以及任何相关的代谢、环境和行为风险因素的全面和最新的了解,对于公共卫生专家和政策制定者

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
    2021-12-05 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
    2022-06-19 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
    2022-05-26 guojianrong
  6. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
    2021-09-08 云舒

    管理

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1962593, encodeId=70111962593d5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 05 04:35:40 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028394, encodeId=163c202839413, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Aug 05 00:35:40 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872278, encodeId=087118e22782e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 10 10:35:40 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896888, encodeId=dd70189688810, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 19 12:35:40 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888336, encodeId=5a831888336ee, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 26 00:35:40 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893413, encodeId=675e189341347, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 18 04:35:40 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015773, encodeId=8f8b1015e7324, content=管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/61deb584a399410ca9b720adee4e6850/71825fee35134aee90c3ed9dfe89b69f.jpg, createdBy=3cff5430616, createdName=云舒, createdTime=Wed Sep 08 20:15:17 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318390, encodeId=23de131839065, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 05 12:35:40 CST 2021, time=2021-09-05, status=1, ipAttribution=)]

相关资讯

Science:中年发福真的能甩锅给代谢变慢吗?

最近,研究人员分析了一个大型的、多样化的数据库,通过双标记水法测量了年龄从8天至95岁的男性和女性的总支出。

Nature:大脑-脂肪回路控制肥胖症 

该研究确定了一个神经-间质单位,它将来自长距离神经回路的线索转化为脂肪驻留的ILC2功能,从而塑造了宿主的代谢和肥胖。

JCEM:代谢和心理特征与胃袖状切除术患者体重减轻有关

患者基线代谢和心理特征与体重减轻独立相关,并对LSG反应有着不可忽视的影响。这些数据表明,对患者代谢和心理分析可以帮助识别更适应LSG的候选人。

NATURE:颠覆!肿瘤中疯狂消耗葡萄糖的不是癌细胞

值得注意的是,在一系列癌症模型中,髓细胞摄取肿瘤环境中葡萄糖的能力最强,其次是T细胞和癌细胞。相比之下,癌细胞对谷氨酰胺的摄取能力最高。

J Clin Invest:约伯综合征患者的血管生成和细胞外基质代谢受损

目前有超过7000种罕见疾病,大多数缺乏具体的治疗方案。常染色体显性高IgE综合征(AD-HIES,又称约伯综合征)是由STAT3的突变导致,患者表现为免疫缺陷,并伴有严重的非免疫学特征,包括骨骼、结

拓展阅读

JAHA:心理治疗对心力衰竭和缺血性心脏病患者预后的影响

针对焦虑或抑郁的心理健康治疗对心血管疾病患者的预后有显著影响,包括减少住院、急诊就诊,并在某些情况下提高生存率。

Nat Rev Cardiol:非编码 RNA 作为缺血性心脏病的治疗靶点和生物标志物

尽管成年心脏的复杂性和修复能力有限,但非编码RNA(ncRNA)作为潜在的治疗靶点和个性化生物标志物,在缺血性心脏病和心力衰竭的治疗中具有重要的临床价值和挑战。

Eur J Heart Fail:流感疫苗接种与缺血性心脏病和心力衰竭患者心血管事件的关系

在这项荟萃分析现有的心血管高危患者随机对照试验中,与安慰剂或未接种流感疫苗相比,流感疫苗接种与心血管事件、心血管死亡和全因死亡发生率降低相关。

每一口含糖饮料都要命!中国疾控中心研究:近30年我国含糖饮料死亡人数翻倍

含糖饮料最常导致的慢性病是糖尿病和缺血性心脏病。从1990年到2019年,因缺血性心脏病和糖尿病死亡的人数分别增加了95%和94%。

糖尿病二线老药焕发新机!Neurology:该药可降低16%痴呆风险,这些人还获益更大...

Neurology:有缺血性中风病史的糖尿病患者使用吡格列酮可降低痴呆风险

JAHA:吸烟导致的缺血性心脏病全球、地区和国家负担

尽管在过去30年里,80%的国家或地区由吸烟引起的缺血性心脏病负担有所下降,但在中低收入国家,尤其是在男性和老年人口中,这仍然是一个重大问题。

2019 TES临床实践指南:存在代谢风险患者ASCVD和T2DM的一级预防

美国内分泌学会(TES,The Endocrine Society) · 2019-07-31